CG'806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3.

被引：0
|
作者：
Zhang, Weiguo [1 ]
Zhang, Hongying [2 ]
Local, Andrea [2 ]
Rice, William G. [2 ]
Ly, Charlie J. [1 ]
Yu, Guopan [1 ]
Howell, Stephen B. [3 ]
Andreeff, Michael [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Aptose Biosci, San Diego, CA USA
[3] UCSD Canc Ctr, La Jolla, CA USA
来源：
CLINICAL CANCER RESEARCH | 2017年 / 23卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
25
引用
收藏
页码：49 / 50
页数：2
相关论文
共 50 条
  • [21] A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
    Yamaura, Takeshi
    Nakatani, Toshiyuki
    Uda, Ken
    Ogura, Hayato
    Shin, Wigyon
    Kurokawa, Naoya
    Saito, Koichi
    Fujikawa, Norie
    Date, Tomomi
    Takasaki, Masaru
    Terada, Daisuke
    Hirai, Atsushi
    Akashi, Akimi
    Chen, Fangli
    Adachi, Yoshiya
    Ishikawa, Yuichi
    Hayakawa, Fumihiko
    Hagiwara, Shinji
    Naoe, Tomoki
    Kiyoi, Hitoshi
    BLOOD, 2018, 131 (04) : 426 - 438
  • [22] Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation
    Kharazi, Shabnam
    Mead, Adam J.
    Mansour, Anna
    Hultquist, Anne
    Boiers, Charlotta
    Luc, Sidinh
    Buza-Vidas, Natalija
    Ma, Zhi
    Ferry, Helen
    Atkinson, Debbie
    Reckzeh, Kristian
    Masson, Kristina
    Cammenga, Jorg
    Ronnstrand, Lars
    Arai, Fumio
    Suda, Toshio
    Nerlov, Claus
    Sitnicka, Ewa
    Jacobsen, Sten Eirik W.
    BLOOD, 2011, 118 (13) : 3613 - 3621
  • [23] CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
    Jetani, Hardikkumar
    Garcia-Cadenas, Irene
    Nerreter, Thomas
    Thomas, Simone
    Rydzek, Julian
    Briones Meijide, Javier
    Bonig, Halvard
    Herr, Wolfgang
    Sierra, Jordi
    Einsele, Hermann
    Hudecek, Michael
    LEUKEMIA, 2018, 32 (05) : 1168 - 1179
  • [24] CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status
    Yu, Guopan
    Zhang, Weiguo
    Ly, Charlie
    Zhang, Hongying
    Rice, William
    Andreeff, Michael
    BLOOD, 2017, 130
  • [25] The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations
    Zhang, Weiguo
    Borthakur, Gautam
    Gao, Chen
    Chen, Ye
    Mu, Hong
    Ruvolo, Vivian R.
    Nomoto, Kenichi
    Zhao, Nanding
    Konopleva, Marina
    Andreeff, Michael
    CANCER RESEARCH, 2016, 76 (06) : 1528 - 1537
  • [26] CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas
    Rastgoo, Nasrin
    Thayer, Matthew
    Benbatoul, Khalid
    Howell, Stephen
    Rice, William
    Zhang, Hongying
    CANCER RESEARCH, 2020, 80 (16)
  • [27] FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations - FLT3 in AML: Much more to learn about biology and optimal targeting
    Giles, Francis J.
    LEUKEMIA RESEARCH, 2006, 30 (12) : 1469 - 1470
  • [28] Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling
    Taylor, Samuel J.
    Dagger, Samantha A.
    Thien, Christine B. F.
    Wikstrom, Matthew E.
    Langdon, Wallace Y.
    BLOOD, 2012, 120 (19) : 4049 - 4057
  • [29] Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD Mutated AML Following Allogeneic Hematopoietic Cell Transplantation
    Liang, Emily C.
    Chen, Connie
    Lu, Rong
    Mannis, Gabriel N.
    Muffly, Lori
    BLOOD, 2021, 138
  • [30] Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation
    Liang, Emily C.
    Chen, Connie
    Lu, Rong
    Mannis, Gabriel N.
    Muffly, Lori
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S278 - S279
12345